MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/08465371251334929

Медицинская библиотека · Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes · 2025

18F-FDG PET/CT for the Detection of Immune-Related Adverse Events in Patients With Metastatic Melanoma Receiving Immunotherapy.

Murad Vanessa, Metser Ur, Kohan Andres, Murad Sarah, Veit-Haibach Patrick, Ortega Claudia

СтатьяНаблюдательное исследованиеПеревод в очереди

Аннотация

Purpose: To evaluate frequency and distribution of immune-related adverse events detected by 18F-FDG PET/CT in patients with metastatic melanoma undergoing immunotherapy. Materials and

Methods

Retrospective observational cohort study evaluating 147 patients with metastatic melanoma treated with immunotherapy and referred for therapy response assessment with 18F-FDG PET/CT at our institution from January 2010 to August 2022. In total, 201 PET/CT scans performed at various time points were analyzed. IRAEs detected on PET/CT were compared against clinical reference standards, including physical examinations, laboratory tests, and biopsies. Diagnostic performance metrics (sensitivity, specificity, positive predictive value, negative predictive value), and diagnostic yields were calculated.

Results

There were 36/147 patients (24.5%) with IRAEs recorded according to standard of reference, with 39 IRAEs in the entire cohort. At time point level, PET/CT identified 36/36 (100%) patients with IRAEs confirmed by the reference standard, while clinical suspicion identified 26/36 (72%) cases. At IRAE level, PET/CT identified 36/39 (92%) of IRAEs confirmed by the reference standard. Thirteen out of 39 (33.3%) cases identified on PET/CT were not suspected clinically but confirmed by the reference standard. The most frequent IRAEs, both suspected clinically and on PET/CT, corresponded to thyroiditis and colitis. Among the PET/CT positive cases, the majority corresponded to grade 2 severity.

Conclusion

18F-FDG PET/CT is highly effective in detecting IRAEs in patients with metastatic melanoma on immunotherapy, uncovering clinically unsuspected events in up to 33% of cases. These results highlight its important role in early detection, guiding timely interventions, and improving overall outcomes of immunotherapy-related toxicities.

Для цитирования: Murad Vanessa, Metser Ur, Kohan Andres, Murad Sarah, Veit-Haibach Patrick, Ortega Claudia. 18F-FDG PET/CT for the Detection of Immune-Related Adverse Events in Patients With Metastatic Melanoma Receiving Immunotherapy.. Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes. 2025. DOI: 10.1177/08465371251334929.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.